By Michael Erman and Puyaan Singh July 15 (Reuters) – Johnson & Johnson said on Wednesday that its medical device unit underperformed in the second quarter, even as strong sales of Tremfya for
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Jury finds ex-gang leader guilty of murder in Tupac case
By Jack Queen Aug 31 (Reuters) - An ex-street gang leader accused of orchestrating the…
South Korea proposes record $597 billion 2027 budget to supercharge AI investment
By Cynthia Kim, Joyce Lee and Heejin Kim SEOUL, Sept 1 (Reuters) - South Korea…
Global AI boom fuels Asia factory expansion in August
By Leika Kihara Sept 1 (Reuters) - Surging global demand for AI hardware kept Asia's…
